Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK NPM-ALK
- Associated Disease
- anaplastic large cell lymphoma
- Source Database
- CIViC Evidence
- Description
- In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease. Crizotinib was well tolerated in these children.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1241
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/513
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Anaplastic Large Cell Lymphoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23598171
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Sensitivity | true |